Automatic continuous venovenous hemodiafiltration in cardiosurgical patients.
Intermittent substitutive treatments in severely ill patients with acute renal failure are difficult or not suitable because of technical problems and/or hemodynamic instability. Continuous venovenous hemodiafiltration allows an adequate, slow removal of fluid, electrolytes, and waste products by combining diffusive and convective solute transport. Eight patients with acute renal failure, after cardiovascular surgery and cardiogenic shock, were treated by continuous venovenous hemodiafiltration. An automatic system (Equaline System, Amicon Division, USA) was employed. Venous accesses (femoral or subclavian) were used with double lumen catheters. A polysulfone filter (0.4 m2) was used in the study. Blood flow was 30 ml/min and dialysate flow rate 16.6 ml/min. Sterile pyrogen-free hemofiltration substitution fluid was used as dialysate. Mean duration of treatment was 10.3 +/- 3.2 days. After 72 hours blood urea nitrogen levels dropped from 136 +/- 46.13 to 53.5 +/- 12.3 mg/dl and creatinine levels dropped from 6.9 +/- 1.7 to 2.6 +/- 0.9 mg/dl. A controlled steady-state was then maintained. Mean urea clearance was 21 +/- 5.3 ml/min; mean ultrafiltration rate was 20.3 +/- 4.1 L/day. Continuous venovenous hemodiafiltration, with the Equaline System, is effective for the clearance of waste products and is able to maintain perfect fluid balance in catabolic patients with acute renal failure and multiple organ failure.
Caprioli
R
R
Division of Nephrology, Spedali Riuniti di Santa Chiara, Pisa, Italy.
Favilla
G
G
Palmarini
D
D
Comite
C
C
Gemignani
R
R
Rindi
P
P
Cioni
L
L
D058186:Acute Kidney Injury / Q000097:blood / Q000628:therapy*; D000368:Aged; D001806:Blood Urea Nitrogen; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood / Q000601:surgery*; D003404:Creatinine / Q000097:blood; D004867:Equipment Design; D005260:Female; D006349:Heart Valve Diseases / Q000097:blood / Q000601:surgery*; D006440:Hemofiltration / Q000295:instrumentation*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D011183:Postoperative Complications / Q000097:blood / Q000628:therapy*; D012770:Shock, Cardiogenic / Q000097:blood / Q000628:therapy; D012772:Shock, Septic / Q000097:blood / Q000628:therapy; D014508:Urea / Q000097:blood
D014508:Urea; D003404:Creatinine